Regulatory uniQure sets course to US filing for Huntington gene therapy PharmaphorumShares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.NeuroscienceRead full story pharminent June 17, 2026 (Last updated: June 18, 2026) Pharmaphorum Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington’s gene therapy AMT-130. Neuroscience Read full story Post navigation Previous: Jazz orchestrates a $4bn cancer alliance with AbCelleraNext: UniQure to file gene therapy for approval, reflecting major shifts at FDA Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
